药用碳治疗慢性肾衰竭血液透析患者高磷血症临床观察  

Medicinal Carbon Treatment of Chronic Renal failure Hyperphosphatemia in Hemodialysis Patients with Clinical Observation

作　　者：钟春梅[1] 李正良[1] 

机构地区：[1]四川省自贡市第三人民医院肾内科,自贡643020

出　　处：《中国中西医结合肾病杂志》2011年第3期229-230,共2页Chinese Journal of Integrated Traditional and Western Nephrology

摘　　要：目的:探讨药用碳治疗慢性肾衰竭血液透析患者高磷血症的疗效及安全性。方法:采用药用碳治疗慢性肾衰竭血液透析患者并高磷血症患者8周,共60例。测定服用药物前后血钙、血磷及血全段甲状旁腺素(iPTH)并观察不良反应。结果:治疗前后血磷由(2.38±0.82)mmol/L降为(1.84±0.81)mmol/L,P<0.05。治疗前后血钙、iPTH无显著变化。胃肠道路反应发生率23%。结论:药用碳是治疗慢性肾衰竭血液透析患者高磷血症有效、安全药物。Objective：To investigate the treatment of chronic renal failure me-dicinal carbon hyperphosphatemia in hemodialysis patients the efficacy and s-afety.Methods：Medicinal carbon treatrent of chronic renal failure and hemo-dialysis patients with hyperphosphatemia 8 weeks,a total of 60 cases.Deter-mination of drugs before and after calcium,phosphorus and serum parathyroid hormone（iPTH） and observe the adverse reactions.Results：Before and after treatment by the phosphorus（2.38±0.82） mmol/L reduced（1.84 ± 0.81） mmol/L,P0.05.Before and after treatment serum calcium,iPTH did not change significantly.The incidence of gastrointestinal reactions roads 23%.Conclusion：On medicinal carbon is treatment of hemodialysis patients with chronic renal failure hyperphosphatemia effective and safe drug.

关 键 词：药用碳 血液透析 高磷血症 

分 类 号：R692.5[医药卫生—泌尿科学]